New drug golidocitinib tested for Hard-to-Treat ITP
NCT ID NCT07196163
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 27 times
Summary
This study tests an experimental drug, golidocitinib, in 138 adults with primary immune thrombocytopenia (ITP) whose platelet counts remain low despite prior treatments. The study has two parts: first, finding a safe dose, then comparing the drug to a placebo in a blinded fashion. The main goal is to see if the drug can safely raise platelet counts to a stable level.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE THROMBOCYTOPENIA (ITP) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University Insititute of Hematology, Peking University People's Hospital
Beijing, Beijing Municipality, 100010, China
Conditions
Explore the condition pages connected to this study.